Strs Ohio Has $16.82 Million Holdings in IQVIA Holdings Inc. $IQV

Strs Ohio lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 14.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,640 shares of the medical research company’s stock after selling 17,206 shares during the quarter. Strs Ohio owned 0.06% of IQVIA worth $16,822,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA in the 4th quarter valued at $25,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA during the 4th quarter worth about $27,000. Gilpin Wealth Management LLC acquired a new stake in shares of IQVIA during the 4th quarter worth about $27,000. CrossGen Wealth LLC bought a new position in IQVIA during the 4th quarter valued at about $28,000. Finally, Measured Wealth Private Client Group LLC acquired a new position in IQVIA in the third quarter valued at about $30,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

Shares of IQV stock opened at $206.38 on Friday. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm’s 50 day moving average is $176.95 and its 200-day moving average is $189.30. The firm has a market capitalization of $34.44 billion, a price-to-earnings ratio of 25.57, a PEG ratio of 1.78 and a beta of 1.20.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter last year, the business posted $2.70 earnings per share. IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has approved a share buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

IQV has been the subject of several recent analyst reports. Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Robert W. Baird increased their price target on IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research report on Wednesday. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and raised their price target for the company from $174.00 to $213.00 in a report on Monday, March 9th. Weiss Ratings downgraded IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Finally, Evercore reissued an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $222.00.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.